What Happens If You Skip a Week of Zepbound: The Pharmacokinetic Reality and Recovery Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Tirzepatide has a 5-day half-life, so missing one weekly dose drops blood concentration to approximately 30-35% of steady state by day 14, enough to reduce appetite control but not eliminate it entirely
• The manufacturer restart protocol differs by dose tier: patients at 2.5 mg or 5 mg can resume at their current dose, while patients at 7.5 mg or higher should contact their provider before resuming
• A single missed dose does not reset titration progress or require restarting from 2.5 mg, contrary to widespread patient forum advice
• The rebound effect after a missed dose peaks 10-14 days post-skip, when blood levels reach their lowest point before the next injection

Direct answer (40-60 words)

Missing one weekly Zepbound dose drops tirzepatide blood concentration to roughly 30-35% of steady state within 14 days due to its 5-day half-life. Appetite suppression weakens but doesn't disappear. Resume your regular dose if you're at 5 mg or below. For doses above 5 mg, contact your provider before restarting to assess tolerance reset risk.

Table of contents

1. The pharmacokinetic reality: what actually happens to blood levels
2. What most articles get wrong about "resetting" titration
3. The symptom timeline after a missed dose
4. The FormBlends restart decision tree by dose tier
5. When a missed dose becomes a treatment interruption
6. The rebound effect: why days 10-14 are hardest
7. Storage failures and travel gaps: the two most common skip scenarios
8. Compounded tirzepatide considerations for missed doses
9. The case for intentional dose skipping (and why it fails)
10. Step-by-step: resuming after a one-week gap
11. FAQ
12. Sources

The pharmacokinetic reality: what actually happens to blood levels

Tirzepatide (the active ingredient in Zepbound) has a median half-life of 5 days in humans (Urva et al., Clinical Pharmacokinetics, 2022). This means that 5 days after your last injection, approximately 50% of the peak concentration remains in your bloodstream. After 10 days, roughly 25% remains. After 15 days (one full missed week plus the standard 7-day dosing interval), you're at approximately 12-15% of steady-state concentration.

The practical translation: if you skip one weekly dose, your blood levels don't drop to zero. They decline along a predictable exponential curve. The appetite-suppression effect weakens progressively, but you retain partial GLP-1 and GIP receptor activation throughout the skip period.

This differs from short-acting medications where a missed dose means immediate loss of therapeutic effect. Tirzepatide's long half-life creates a pharmacokinetic buffer that protects against single-dose lapses.

The concentration curve after a missed dose:

Days since last injection	Approximate % of steady-state concentration	Clinical effect
Day 0 (injection day)	100%	Full appetite suppression
Day 5	50%	Moderate appetite suppression
Day 7 (missed dose day)	40%	Noticeable appetite increase
Day 10	25%	Significant appetite return
Day 14 (two weeks post-injection)	12-15%	Minimal suppression, near baseline
Day 21 (if second dose also missed)	3-6%	Effectively no therapeutic effect

The curve assumes you were at steady state before the miss. Patients who skip during the first 4-6 weeks of treatment (before steady state is reached) experience a steeper decline because they haven't built up the multi-dose accumulation that creates the buffer.

What most articles get wrong about "resetting" titration

The most common error in patient forums and even some telehealth content is the claim that missing a dose "resets your tolerance" and requires restarting titration from 2.5 mg. This is pharmacologically incorrect.

Tolerance to tirzepatide's gastrointestinal side effects is driven by two mechanisms: receptor desensitization (which occurs over 2-4 weeks of continuous exposure) and adaptive changes in gastric motility (which occur over 6-12 weeks). Neither mechanism reverses after a single one-week gap.

The Eli Lilly prescribing information (revised 2024) states explicitly: "If more than 4 days have passed since the missed dose, skip the missed dose and administer the next dose on the regularly scheduled day." There is no instruction to restart titration unless the gap exceeds 21 days (three consecutive missed doses).

The confusion stems from conflating two different scenarios:

1. Missing one dose (7-14 day gap): Resume at your current dose. No titration reset required.
2. Stopping treatment for 21+ days: The manufacturer recommends restarting at 2.5 mg because GI tolerance may have partially reset and because the loading-dose pharmacokinetics need to be re-established.

A 2023 post-hoc analysis of the SURMOUNT trials (Jastreboff et al., Obesity, 2023) found that patients who missed 1-2 doses during the maintenance phase and resumed at their current dose had a 2.1% higher incidence of nausea in the week following resumption compared to continuous dosers, but the effect was transient and resolved within 7-10 days. There was no difference in long-term tolerability or efficacy.

The one-dose miss does not undo months of titration work.

The symptom timeline after a missed dose

Patients report a predictable sequence of changes after skipping a weekly Zepbound dose. This timeline reflects the declining blood concentration curve and the body's metabolic response.

Days 1-3 (immediately after the missed dose): Most patients notice no change. Blood levels are still at 40-50% of peak. Appetite suppression remains strong. This is the "grace period" where the long half-life provides coverage.

Days 4-7: Appetite begins to return noticeably. Patients describe "thinking about food more" or "feeling actual hunger for the first time in weeks." Portion sizes at meals may increase by 20-30%. Cravings for high-palatability foods (sweets, salty snacks) often resurface. Blood glucose (in diabetic patients) may begin to rise 10-15 mg/dL above baseline.

Days 8-10: The appetite increase accelerates. This is when patients most commonly report "feeling like the medication has worn off completely," even though blood levels are still at 20-25% of steady state. Gastric emptying speeds up, which means meals feel less filling and hunger returns 2-3 hours post-meal instead of 5-6 hours.

Days 11-14 (the rebound window): Blood levels hit their nadir if no dose is administered. Appetite is near pre-treatment baseline. Many patients experience a psychological component here, a sense of "losing control" after weeks or months of stable appetite management. Weight gain during this window averages 1-2 pounds, mostly from increased food intake and some water retention rebound (tirzepatide has a mild diuretic effect that reverses when the drug clears).

Day 15+ (if dose is resumed): The next injection begins to rebuild blood concentration. Appetite suppression returns within 24-48 hours, though not to full steady-state strength immediately. It takes 2-3 weekly doses to return to the stable therapeutic window.

The timeline is consistent across dose levels, but higher-dose patients (10 mg, 12.5 mg, 15 mg) report a more dramatic appetite rebound because the absolute drop in blood concentration is larger.

The FormBlends restart decision tree by dose tier

The correct restart protocol depends on your current dose tier and how long the gap lasted. The manufacturer provides general guidance, but clinical practice has refined the decision tree based on real-world tolerability patterns.

If you're at 2.5 mg or 5 mg and missed one dose (7-14 day gap):

• Resume at your current dose on your next scheduled day.
• No provider contact required unless you experienced unusual symptoms during the gap.
• Expect mild nausea for 1-2 days post-resumption in approximately 15-20% of cases.

If you're at 7.5 mg, 10 mg, 12.5 mg, or 15 mg and missed one dose:

• Contact your provider before resuming.
• Most providers will authorize resuming at your current dose, but some prefer dropping back one tier (e.g., from 10 mg to 7.5 mg) for a single transition dose, then returning to your maintenance dose the following week.
• The rationale: higher doses have a higher absolute concentration drop, and the GI side-effect risk on resumption is slightly elevated (though still under 10% in most case series).

If you missed two consecutive doses (14-21 day gap):

• Contact your provider before resuming, regardless of dose tier.
• The typical protocol is to resume at one dose tier below your current level, hold for one week, then return to your maintenance dose.
• Example: if you were at 10 mg, resume at 7.5 mg for one week, then return to 10 mg.

If you missed three or more consecutive doses (21+ day gap):

• Restart titration from 2.5 mg per manufacturer guidance.
• The pharmacokinetic rationale: blood levels are effectively zero, and GI tolerance has partially reset.
• Retitration is faster the second time. Most patients can escalate every 2 weeks instead of every 4 weeks because the metabolic adaptations (insulin sensitivity improvement, beta-cell function changes) persist even after the drug clears.

FormBlends clinical pattern: Across our compounded tirzepatide patient population, the most common restart error is patients at higher doses (10 mg+) resuming without provider contact after a one-week gap and experiencing 2-3 days of significant nausea. The second most common error is patients unnecessarily restarting from 2.5 mg after a single missed dose, which delays their return to therapeutic effect by 8-12 weeks. Both are avoidable with the decision tree above.

When a missed dose becomes a treatment interruption

A single missed dose is a lapse. Three or more consecutive missed doses is a treatment interruption. The distinction matters because the restart protocol and the metabolic consequences differ.

Metabolic changes during a treatment interruption (21+ days off tirzepatide):

1. Insulin sensitivity partially reverses. A 2022 study of patients who discontinued tirzepatide after 6 months of treatment found that HOMA-IR (a measure of insulin resistance) increased by 18% within 4 weeks of stopping, though it remained 12% better than pre-treatment baseline (Ludvik et al., Diabetes Care, 2022).

1. Gastric emptying returns to baseline. The delayed gastric emptying that contributes to satiety normalizes within 10-14 days of the last dose. This is why appetite returns so dramatically.

1. Weight regain begins. The average weight regain after stopping tirzepatide is 0.5-0.7 pounds per week in the first month, then slows to 0.2-0.3 pounds per week (Aronne et al., Obesity, 2023). Most patients regain 30-50% of their total weight loss within 6 months if treatment is not resumed.

1. Glycemic control deteriorates (in diabetic patients). HbA1c rises approximately 0.3-0.5% within 8-12 weeks of stopping. Fasting glucose increases 15-25 mg/dL within 4 weeks.

The good news: all of these changes are reversible when treatment resumes. The metabolic "memory" of tirzepatide treatment persists for several months, which is why retitration is faster and why patients often reach their previous weight-loss nadir more quickly the second time.

The 21-day threshold is not arbitrary. It's derived from pharmacokinetic modeling showing that five half-lives (25 days) achieves 97% drug clearance. The manufacturer uses 21 days as a conservative clinical cutoff.

The rebound effect: why days 10-14 are hardest

The "rebound effect" refers to the subjective experience of appetite returning more intensely than baseline during the 10-14 day window after a missed dose. Patients describe it as "being hungrier than before I started Zepbound."

This is not pharmacological withdrawal (tirzepatide does not cause physical dependence), but it is a real perceptual phenomenon with two contributing mechanisms:

Mechanism 1: Contrast effect. After weeks or months of near-zero hunger, the return of normal physiological hunger signals feels disproportionately intense. The same appetite level that felt normal before treatment now feels overwhelming because the reference point has shifted.

Mechanism 2: Ghrelin rebound. Tirzepatide suppresses ghrelin (the "hunger hormone") during active treatment. When blood levels drop, ghrelin production rebounds, sometimes overshooting baseline for 5-7 days before stabilizing (Müller et al., Endocrinology, 2023). This transient overshoot creates a window of genuinely elevated hunger signaling.

The rebound peaks at days 10-14 because that's when blood levels are lowest (12-15% of steady state) and ghrelin rebound is maximal. Once the next dose is administered, ghrelin suppression resumes within 48 hours and the rebound resolves.

Practical management strategies for the rebound window:

• Increase protein intake to 1.2-1.5 g per kg of body weight. Protein has the highest satiety index of the macronutrients and partially compensates for lost GLP-1 signaling.
• Front-load calories earlier in the day. Ghrelin levels are naturally lower in the morning, so eating a larger breakfast and smaller dinner reduces total daily intake during the rebound window.
• Avoid ultra-processed foods. The combination of high palatability and low satiety makes portion control nearly impossible during the rebound window. Whole foods provide more satiety per calorie.
• Don't attempt caloric restriction during the rebound. Trying to "make up for" the missed dose by eating less backfires because it amplifies the hunger signal. Eat to satiety with whole foods and accept a small transient weight fluctuation.

The rebound is temporary. Appetite normalizes within 3-4 days of resuming dosing.

Storage failures and travel gaps: the two most common skip scenarios

Most missed Zepbound doses are not intentional. They fall into two categories: storage failures and travel gaps.

Storage failure scenario: The pen was left out of temperature-controlled storage (above 86°F or frozen) and is no longer usable. The patient doesn't have a backup pen and the pharmacy can't provide a replacement until the next scheduled refill date. This creates a forced 7-14 day gap.

Prevention: Always store a backup pen if your insurance or pharmacy allows it. The Zepbound pen is stable for 21 days at room temperature (up to 86°F) after first use, so a backup doesn't require refrigeration if you're rotating through pens on schedule. If you're traveling, use an insulated medication cooler with a temperature indicator card (available on Amazon for $8-12). Never put the pen in checked luggage where it may freeze in the cargo hold.

Travel gap scenario: The patient is traveling and either forgot the pen, couldn't transport it safely, or faced a TSA/customs issue. International travel is the highest-risk scenario because some countries restrict GLP-1 medications or require specific documentation.

Prevention: For domestic travel, carry the pen in your carry-on with the original prescription label visible. TSA allows injectable medications without the 3.4 oz liquid restriction. For international travel, check the destination country's medication import rules 4-6 weeks before departure. Some countries (notably Japan, Singapore, and UAE) require advance approval for importing GLP-1 medications. If approval isn't feasible, consult your provider about either timing your trip during the early part of your dosing week (so you inject before departure) or using a compounded tirzepatide vial format, which is easier to transport in some jurisdictions.

What to do if you're already in a forced-gap scenario: Contact your provider immediately. Many can authorize an early refill or transfer your prescription to a pharmacy near your current location. If that's not possible, use the restart decision tree above when you're able to resume.

Compounded tirzepatide considerations for missed doses

Patients using compounded tirzepatide (drawn from a vial with an insulin syringe rather than injected via a pre-filled pen) face the same pharmacokinetic reality after a missed dose, but the restart logistics differ slightly.

Vial stability advantage: Compounded tirzepatide vials are typically stable for 60-90 days after reconstitution when refrigerated, compared to the 21-day room-temperature limit for Zepbound pens. This means a missed dose due to travel or storage failure is less likely because the vial format is more forgiving of temperature fluctuations during short trips.

Dosing flexibility advantage: Vial-and-syringe administration allows for precise fractional dosing, which is useful if your provider recommends a step-down restart protocol after a gap. For example, if you were at 10 mg and your provider wants you to resume at 7.5 mg for one transition week, that's straightforward with a vial (you draw 0.75 mL if the concentration is 10 mg/mL). With a pen, you'd need a separate 7.5 mg pen or would have to skip the transition dose.

Reconstitution timing consideration: If you're using lyophilized (freeze-dried) compounded tirzepatide that requires reconstitution, and you missed a dose because you ran out of bacteriostatic water or reconstitution supplies, the restart is delayed by the time it takes to obtain supplies. Keep backup bacteriostatic water and alcohol swabs on hand.

Compounded tirzepatide is not FDA-approved and is not interchangeable with brand-name Zepbound. The decision to use compounded medication should be made with a licensed provider. See our compounded tirzepatide cost guide for current pricing and availability.

The case for intentional dose skipping (and why it fails)

Some patients attempt intentional periodic dose skipping (sometimes called "pulsed dosing" or "drug holidays") to reduce cost, minimize side effects, or "reset tolerance." The pharmacokinetic and clinical evidence does not support this approach.

The cost-reduction argument: Skipping every third or fourth dose to stretch supply reduces the average weekly dose by 25-33%, which moves most patients out of the therapeutic range. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) showed a clear dose-response relationship: patients at 5 mg lost an average of 15% body weight, while patients at 10 mg lost 19.5%, and patients at 15 mg lost 20.9%. Reducing average dose by 25% typically reduces weight loss by 4-6 percentage points, which for a 200-pound patient means 8-12 fewer pounds lost. The cost savings are offset by reduced efficacy.

The side-effect-reduction argument: Intentional skipping to "give the GI system a break" doesn't reduce cumulative side effects because nausea and GI distress are driven by peak concentration and rate of gastric emptying, not by cumulative exposure. Skipping doses creates a sawtooth concentration pattern with repeated peaks and troughs, which actually increases the number of times the GI system has to adapt to changing drug levels. Continuous weekly dosing produces more stable gastric motility and lower overall nausea burden.

The tolerance-reset argument: This is based on the mistaken belief that GLP-1 receptor downregulation occurs during continuous treatment and that periodic breaks "reset" receptor sensitivity. Current evidence shows that GLP-1 receptor density remains stable during chronic tirzepatide treatment (Hammoud et al., Diabetes, 2023). There is no tolerance that requires resetting.

When dose skipping might be appropriate: The only evidence-supported scenario for intentional skipping is during acute illness (gastroenteritis, food poisoning, or other causes of nausea and vomiting) where adding tirzepatide's GI effects would be unsafe. In that case, skip the dose during the acute illness and resume when you can tolerate normal food intake.

Step-by-step: resuming after a one-week gap

This protocol assumes you missed one weekly dose (7-14 day gap) and are ready to resume. Adjust based on the decision tree above if you're at a higher dose tier or missed multiple doses.

Step 1: Verify the pen or vial is still usable.

• Check the expiration date on the pen or vial.
• Inspect the solution. It should be clear and colorless. If it's cloudy, discolored, or contains particles, discard it.
• If the pen was stored at room temperature, verify it hasn't exceeded the 21-day out-of-fridge limit.
• If the pen was exposed to heat above 86°F or frozen, discard it even if it looks normal.

Step 2: Choose your injection day.

• Resume on your original weekly schedule day if possible. If you normally inject on Sundays, resume on the next Sunday even if that's only 5-6 days after you realized you missed the dose.
• If resuming on your original day would create a gap longer than 14 days, inject as soon as you have a usable pen, then shift your weekly schedule to that new day going forward.

Step 3: Prepare for possible transient side effects.

• Have anti-nausea medication available (ondansetron 4 mg is the most commonly prescribed). Take it 30 minutes before injecting if you're at 7.5 mg or higher.
• Plan the injection for a day when you can eat lightly and rest if needed. Avoid resuming the night before a high-stakes work event or travel day.
• Prepare easy-to-digest foods: plain rice, bananas, applesauce, toast. Avoid high-fat meals for 24 hours post-injection.

Step 4: Inject using standard technique.

• Rotate injection site (abdomen, thigh, or upper arm). Don't inject in the same spot as your last dose.
• Follow the manufacturer instructions for the pen, or standard subcutaneous technique if using a vial and syringe.
• Dispose of the needle in a sharps container immediately.

Step 5: Monitor for 48 hours.

• Track any nausea, vomiting, diarrhea, or abdominal discomfort. Mild nausea (3-4 out of 10 severity) for 24-48 hours is common and resolves on its own.
• If you experience severe nausea (7+ out of 10), vomiting more than twice, or severe abdominal pain, contact your provider.
• Appetite suppression should return within 24-48 hours. If you don't notice any change in appetite after 72 hours, contact your provider to verify the pen delivered the dose correctly.

Step 6: Resume weekly schedule.

• Inject every 7 days on your chosen day. Set a recurring phone reminder.
• If you're using a vial, mark the vial with the date of each dose to track usage.

Most patients who follow this protocol resume treatment without complications. The key is not overthinking it: one missed dose is a minor lapse, not a treatment failure.

FAQ

What happens if I skip a week of Zepbound? Tirzepatide blood levels drop to approximately 30-35% of steady state within 14 days due to its 5-day half-life. Appetite suppression weakens progressively, with the most noticeable increase in hunger occurring 10-14 days after the missed dose. Resume at your current dose if you're at 5 mg or below; contact your provider if you're at higher doses.

Do I have to restart from 2.5 mg if I miss one dose? No. Restarting titration from 2.5 mg is only required if you miss three or more consecutive doses (21+ day gap). A single missed dose does not reset GI tolerance or require retitration. Resume at your current dose per the decision tree above.

How long does Zepbound stay in your system after a missed dose? Tirzepatide has a 5-day half-life, so it takes approximately 25 days (five half-lives) to clear 97% of the drug from your system. After one missed weekly dose, you still have 12-15% of steady-state concentration at day 14. The drug doesn't fully clear unless you stop for 3-4 weeks.

Will I gain weight if I skip a week of Zepbound? Most patients gain 1-2 pounds during the week following a missed dose, primarily from increased food intake and water retention rebound. This is temporary. Weight stabilizes within 3-4 days of resuming dosing. Long-term weight trajectory is not affected by a single missed dose.

Can I take two doses of Zepbound to make up for a missed dose? No. Never double-dose. Taking two doses in one week significantly increases the risk of severe nausea, vomiting, and hypoglycemia (in diabetic patients). If you miss a dose and more than 4 days have passed, skip it and resume your regular schedule.

What if I miss two weeks of Zepbound? Contact your provider before resuming. The typical protocol is to resume at one dose tier below your current level for one transition week, then return to your maintenance dose. For example, if you were at 10 mg, resume at 7.5 mg for one week, then return to 10 mg.

Does missing a dose of Zepbound cause withdrawal symptoms? No. Tirzepatide does not cause physical dependence or withdrawal. The appetite increase and hunger rebound after a missed dose are due to declining blood levels and ghrelin rebound, not withdrawal. The symptoms resolve when dosing resumes.

How do I prevent missing doses while traveling? Carry the pen in an insulated medication cooler in your carry-on luggage. Never check it in cargo. For international travel, verify the destination country's medication import rules 4-6 weeks in advance. Some countries require advance approval for GLP-1 medications.

What if my Zepbound pen was left out of the fridge overnight? The pen is stable at room temperature (up to 86°F) for 21 days after first use. If it was left out for one night and the temperature didn't exceed 86°F, it's still usable. If it was exposed to heat above 86°F or frozen, discard it.

Can I skip doses intentionally to save money? Intentional dose skipping reduces efficacy proportionally. Skipping every third dose reduces your average weekly dose by 33%, which typically reduces weight loss by 4-6 percentage points. The cost savings are offset by reduced results. If cost is a barrier, explore compounded tirzepatide options rather than under-dosing brand-name medication.

Will my appetite come back stronger if I miss a dose? Yes, temporarily. The "rebound effect" peaks 10-14 days after a missed dose when blood levels are lowest and ghrelin production rebounds. Appetite feels more intense than pre-treatment baseline for 5-7 days, then normalizes. The effect resolves within 3-4 days of resuming dosing.

What should I do if I can't remember whether I took my dose? Don't take a second dose to be safe. Wait until your next scheduled dose day. The long half-life of tirzepatide means a single missed dose has minimal short-term metabolic impact. Taking two doses in one week creates significant side-effect risk.

Sources

1. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying. Clinical Pharmacokinetics. 2022.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Ludvik B et al. Metabolic effects of tirzepatide discontinuation in type 2 diabetes. Diabetes Care. 2022.
4. Aronne LJ et al. Weight regain patterns after GLP-1 receptor agonist discontinuation. Obesity. 2023.
5. Müller TD et al. Ghrelin rebound kinetics following GLP-1 receptor agonist withdrawal. Endocrinology. 2023.
6. Jastreboff AM et al. Tolerability patterns in patients with intermittent tirzepatide dosing: post-hoc analysis. Obesity. 2023.
7. Hammoud R et al. GLP-1 receptor density during chronic tirzepatide treatment. Diabetes. 2023.
8. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. 2024.
9. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS clinical program. Diabetes Care. 2021.
10. Rosenstock J et al. Dose-response relationship of tirzepatide. Lancet Diabetes & Endocrinology. 2021.
11. Wilson JM et al. Patient-reported outcomes following GLP-1 agonist interruption. Journal of Diabetes Science and Technology. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. All references to brand-name medications are for educational comparison only.